with RhD+ RBCs to generate polyclonal anti-RhD. Although this approach is acceptable, it is prone to the inherent biological variability observed when using different human donors and continuously poses a risk of limitations in supply.\(^{10}\) To overcome challenges associated with polyclonal preparations, many attempts have been made to develop monoclonal anti-RhD replacements that display the same efficacy as polyclonal anti-RhD with mixed success.\(^{10}\) Challenges associated with developing equally effective surrogate products in part reflect a complete lack of understanding as to the mechanism(s) responsible for anti-RhD antibody-mediated immunosuppression.

Bernardo et al demonstrate that, although individual monoclonal antibodies do suppress alloimmunization following RBC exposure, combining 2 monoclonal antibodies that recognize distinct RBC alloantigen epitopes results in a level of suppression similar to that observed following injection of polyclonal preparations (see figure). These studies hold significant promise, as these findings suggest that blends of different monoclonal antibodies may provide a satisfactory substitute for the use of polyclonal preparations in the future. Equally important, although anti-RhD antibodies currently prevent antibody formation against RhD antigens, similar approaches do not exist for other RBC alloantigens. Indeed, in the wake of RhD immunoprophylaxis, anti-KEL antibodies are now responsible for more HDFN-related mortality than any other anti-RBC alloantibody. As a result, the present study not only holds promise in the potential development of monoclonal combinations that may replace naturally derived sources for anti-RhD, but may also serve as a platform to provide similar approaches to prevent equally devastating consequences of alloimmunization against other RBC alloantigens. As new models and mechanisms of antibody-mediated immunosuppression become available, studies like these will continue to build on the successful history of RhD immunoprophylaxis to generate better products and thus extend this therapy to patients who continue to suffer from HDFN.

Conflict-of-interest disclosure: The author declares no competing financial interests.

REFERENCES

4. Wiener AS, Peters HR. Hemolytic reactions following transfusions of blood of the homologous group, with three cases in which the same agglutinin was responsible. Am J Med. 1941;42(6):925-937.

DOI 10.1182/blood-2016-07-724889
© 2016 by The American Society of Hematology

Pediatric-type FL: simply different

Shamzah Araf and Jude Fitzgibbon QUEEN MARY UNIVERSITY OF LONDON

In this issue of Blood, the groups of Louissaint et al\(^1\) and Schmidt et al\(^2\) report on the genetic landscape of pediatric-type follicular lymphoma (PTFL). Their studies confirm suspicions that PTFL represents a biologically distinct form of lymphoma, with fewer recurrent genetic alterations than typical FL. Because this group of patients has an excellent prognosis, accurate and reliable identification of PTFL is important to minimize the prospect of unnecessary treatment.

**LYMPHOID NEOPLASIA**

Comment on Louissaint et al, page 1093, and Schmidt et al, page 1101
The 2016 revision of the World Health Organization classification of lymphoid neoplasms promoted follicular lymphoma (FL) from a provisional to a definitive entity, renaming it PTFL to reflect the incidence in both children and adults.1 Although sharing some features with typical adult FL, PTFL is both histologically and clinically distinct, with blastoid cytology, a clear male predominance (10:1), the majority of patients presenting with localized stage 1 lymphadenopathy, a high proliferation index, and exceedingly good response rate either to local excision or minimal chemotherapy2 (see figure). Going forward, and given the existence of PTFL in adults, it is important to distinguish these different endotypes, irrespective of age, to appropriately stratify patients and deescalate therapy where possible. Although it has been recognized that IgH-BCL2 t(14;18) and overexpression of BCL2 protein is absent in PTFL,3 these 2 new studies offer important insights into the genetic makeup of PTFL and provide compelling evidence to support the notion that PTFL is a distinct entity with unique molecular features.

Both Louissaint et al and Schmidt et al used standard next-generation sequencing and copy number profiling approaches to generate a mutational landscape of PTFL in a combined series of 68 patients. The data are remarkably consistent across studies, with PTFLs deemed genetically light, accumulating fewer recurrent mutations or copy number alterations than typical FL. Schmidt et al rule out the possibility of a close genetic relationship linking PTFL and BCL2-negative typical FLs by providing a direct comparison of mutations in these lymphomas. Both studies confirm the previous report by Martin-Guerrero et al5 of a high frequency (>25%) of TNFRSF14 mutations in PTFL and their common association with deletion or copy number–neutral loss of heterozygosity of chromosome 1p, lesions that also characterize typical FL. However, this is where the genetic semblance diverges, with PTFL having a reduced incidence of mutations in the histone methyltransferases KMT2D and EZH2 and the acetyltransferase CREBBP. Although each of these lesions individually affect B-cell biology, their absence in PTFL is noteworthy because it may suggest a link between the presence of epigenetic mutations and the relapsing clinical course of typical FL.

Moreover, phylogenetic analysis6-8 demonstrated that mutations in the key epigenetic regulators represent early events in FL, and their absence along with the lack of t(14;18) suggests that the initiating events of PTFL are wholly distinct. Critically, the whole exome sequencing data in 22 PTFLs by Louissaint et al identify recurrent mutations in different components of the MAPK pathway (MAP2K1 [43%], MAPK1 [9%], and RRAS [4.5%]), implicating activation of the MEK/ERK pathway in lymphomagenesis. Although these mutations are not unique to PTFL and have been reported in rare cases of B-cell lymphomas, including hairy cell leukemia-variant,9 they provide, as the authors rightly propose, an objective parameter to support the diagnosis of PTFL.

Altogether, we must not be complacent in diagnosing PTFL and the possibility of it masquerading as typical FL. This diagnostic challenge was highlighted perfectly by 2 PTFL cases in the Louissaint et al study that presented with mutation profiles analogous to typical FL, suggesting that a reliance on clinical diagnostic criteria alone may not be sufficient in all cases, particularly within the adult population. Further collaborative studies are now needed to better define the frequency of these cases and consider if PTFL patients need to be accounted for in ongoing efforts at developing a clinico-genetic risk score in FL.10 Indeed, although the genomic landscape of typical FL may be better appreciated, these new studies are excellent examples of the significant insights gained from studying rarer subsets of FL.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

REFERENCES

DOI 10.1182/blood-2016-07-725002

© 2016 by The American Society of Hematology
Pediatric-type FL: simply different

Shamzah Araf and Jude Fitzgibbon